RxDoctor Payments Data

Maqbool Ahmed, MD

Hematology & Oncology · Evansville, INNPI 1023022118

Payments from drug & device makers

$60,752in general payments, 2019–2025

Across 634 payments — averaging $95.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$39K
  • Pfizer$5K
  • AstraZeneca$4K
  • Taiho Oncology, Inc.$2K
  • Novartis$2K
  • Merck$1K
  • plus $8K from 45 others

What the payments were for

  • Consulting fees$6,55511%
  • Speaking & faculty fees$38,42663%
  • Travel & lodging$2,2604%
  • Food & beverage$12,56021%
  • Education$9512%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$60,752 in reported general payments places this provider in the 70th percentile of 224 hematology & oncology providers in Indiana.

See all hematology & oncology providers in Indiana

Medicare billing

Part B allowed, 2024
$99,747
Medicare patients
430
Services billed
902

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TagrissoOsimertinib Mesylate11$380,748
Lenalidomide25$379,240
CalquenceAcalabrutinib Maleate12$186,223
ErleadaApalutamide12$174,677
EliquisApixaban18$15,364
Imatinib Mesylate14$11,660
XareltoRivaroxaban12$6,687
Abiraterone Acetate12$5,347
Ondansetron Hcl139$4,482
Anastrozole122$1,393
Prochlorperazine Maleate144$1,160
Lidocaine-PrilocaineLidocaine/Prilocaine53$664
Dexamethasone36$505
Potassium Chloride13$426
Tamoxifen Citrate18$401

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaTagrisso, Calquence$3,575$566,97123 claims
Johnson & JohnsonErleada, Xarelto$808$181,36424 claims
PfizerEliquis$5,166$15,36418 claims
Lilly USA, LLCOlanzapine$166$26522 claims
Teva Pharmaceuticals USA, Inc.Acyclovir$67$8014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 224 hematology & oncology providers in Indiana.

Other hematology & oncology in Evansville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →